284 related articles for article (PubMed ID: 31318944)
21. The Current Genomic and Molecular Landscape of Philadelphia-like Acute Lymphoblastic Leukemia.
Shiraz P; Payne KJ; Muffly L
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32235787
[TBL] [Abstract][Full Text] [Related]
22. Characterization of Philadelphia-like Pre-B Acute Lymphoblastic Leukemia: Experiences in Mexican Pediatric Patients.
Martínez-Anaya D; Moreno-Lorenzana D; Reyes-León A; Juárez-Figueroa U; Dean M; Aguilar-Hernández MM; Rivera-Sánchez N; García-Islas J; Vieyra-Fuentes V; Zapata-Tarrés M; Juárez-Villegas L; Paredes-Aguilera R; Vega-Vega L; Rivera-Luna R; Juárez-Velázquez MDR; Pérez-Vera P
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36076986
[TBL] [Abstract][Full Text] [Related]
23. Effects of different aberrations in the CRLF2 gene on the biological characteristics and drug sensitivities of Nalm6 cells.
Gu M; Jia Y; Xu M; Feng J; Tian Z; Ma X; Wang M; Wang J; Xu Y; Rao Q; Hao L; Mi Y; Yang W
Int J Lab Hematol; 2021 Jun; 43(3):441-449. PubMed ID: 33615710
[TBL] [Abstract][Full Text] [Related]
24. A recombinant antibody fragment directed to the thymic stromal lymphopoietin receptor (CRLF2) efficiently targets pediatric Philadelphia chromosome-like acute lymphoblastic leukemia.
Mohamed SMA; Wohlmann A; Schofield P; Sia KCS; McCalmont H; Savvides SN; Verstraete K; Kavallaris M; Christ D; Friedrich KH; Bayat N; Lock RB
Int J Biol Macromol; 2021 Nov; 190():214-223. PubMed ID: 34481852
[TBL] [Abstract][Full Text] [Related]
25. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.
Roberts KG; Li Y; Payne-Turner D; Harvey RC; Yang YL; Pei D; McCastlain K; Ding L; Lu C; Song G; Ma J; Becksfort J; Rusch M; Chen SC; Easton J; Cheng J; Boggs K; Santiago-Morales N; Iacobucci I; Fulton RS; Wen J; Valentine M; Cheng C; Paugh SW; Devidas M; Chen IM; Reshmi S; Smith A; Hedlund E; Gupta P; Nagahawatte P; Wu G; Chen X; Yergeau D; Vadodaria B; Mulder H; Winick NJ; Larsen EC; Carroll WL; Heerema NA; Carroll AJ; Grayson G; Tasian SK; Moore AS; Keller F; Frei-Jones M; Whitlock JA; Raetz EA; White DL; Hughes TP; Guidry Auvil JM; Smith MA; Marcucci G; Bloomfield CD; Mrózek K; Kohlschmidt J; Stock W; Kornblau SM; Konopleva M; Paietta E; Pui CH; Jeha S; Relling MV; Evans WE; Gerhard DS; Gastier-Foster JM; Mardis E; Wilson RK; Loh ML; Downing JR; Hunger SP; Willman CL; Zhang J; Mullighan CG
N Engl J Med; 2014 Sep; 371(11):1005-15. PubMed ID: 25207766
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in
Zhang Q; Shi C; Han L; Jain N; Roberts KG; Ma H; Cai T; Cavazos A; Tabe Y; Jacamo RO; Mu H; Zhao Y; Wang J; Wu SC; Cao F; Zeng Z; Zhou J; Mi Y; Jabbour EJ; Levine R; Tasian SK; Mullighan CG; Weinstock DM; Fruman DA; Konopleva M
Oncotarget; 2018 Jan; 9(8):8027-8041. PubMed ID: 29487712
[TBL] [Abstract][Full Text] [Related]
27. The prognostic significance of
Wang J; Sun K; Chen WM; Wang X; Li LD; Hao Y; Xu N; Jiang H; Xu LP; Wang Y; Zhang XH; Huang XJ; Jiang Q; Qin YZ
Leuk Lymphoma; 2023 Mar; 64(3):698-706. PubMed ID: 36642937
[TBL] [Abstract][Full Text] [Related]
28. Precision medicine approaches may be the future for CRLF2 rearranged Down Syndrome Acute Lymphoblastic Leukaemia patients.
Page EC; Heatley SL; Yeung DT; Thomas PQ; White DL
Cancer Lett; 2018 Sep; 432():69-74. PubMed ID: 29879498
[TBL] [Abstract][Full Text] [Related]
29. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia.
Harvey RC; Mullighan CG; Chen IM; Wharton W; Mikhail FM; Carroll AJ; Kang H; Liu W; Dobbin KK; Smith MA; Carroll WL; Devidas M; Bowman WP; Camitta BM; Reaman GH; Hunger SP; Downing JR; Willman CL
Blood; 2010 Jul; 115(26):5312-21. PubMed ID: 20139093
[TBL] [Abstract][Full Text] [Related]
30. Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group.
Reshmi SC; Harvey RC; Roberts KG; Stonerock E; Smith A; Jenkins H; Chen IM; Valentine M; Liu Y; Li Y; Shao Y; Easton J; Payne-Turner D; Gu Z; Tran TH; Nguyen JV; Devidas M; Dai Y; Heerema NA; Carroll AJ; Raetz EA; Borowitz MJ; Wood BL; Angiolillo AL; Burke MJ; Salzer WL; Zweidler-McKay PA; Rabin KR; Carroll WL; Zhang J; Loh ML; Mullighan CG; Willman CL; Gastier-Foster JM; Hunger SP
Blood; 2017 Jun; 129(25):3352-3361. PubMed ID: 28408464
[TBL] [Abstract][Full Text] [Related]
31. Understanding the biology of CRLF2-overexpressing acute lymphoblastic leukemia.
Tasian SK; Loh ML
Crit Rev Oncog; 2011; 16(1-2):13-24. PubMed ID: 22150304
[TBL] [Abstract][Full Text] [Related]
32. CRLF2-Positive B-Cell Acute Lymphoblastic Leukemia in Adult Patients: A Single-Institution Experience.
Konoplev S; Lu X; Konopleva M; Jain N; Ouyang J; Goswami M; Roberts KG; Valentine M; Mullighan CG; Bueso-Ramos C; Zweidler-McKay PA; Jorgensen JL; Wang SA
Am J Clin Pathol; 2017 Apr; 147(4):357-363. PubMed ID: 28340183
[TBL] [Abstract][Full Text] [Related]
33. BCL6 inhibition ameliorates resistance to ruxolitinib in
Tsuzuki S; Yasuda T; Goto H; Maeda N; Akahane K; Inukai T; Yamamoto H; Karnan S; Ota A; Hyodo T; Konishi H; Hosokawa Y; Kiyoi H; Hayakawa F
Haematologica; 2023 Feb; 108(2):394-408. PubMed ID: 36005560
[TBL] [Abstract][Full Text] [Related]
34. The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL.
Savino AM; Sarno J; Trentin L; Vieri M; Fazio G; Bardini M; Bugarin C; Fossati G; Davis KL; Gaipa G; Izraeli S; Meyer LH; Nolan GP; Biondi A; Te Kronnie G; Palmi C; Cazzaniga G
Leukemia; 2017 Nov; 31(11):2365-2375. PubMed ID: 28331226
[TBL] [Abstract][Full Text] [Related]
35. Targeting signaling pathways in acute lymphoblastic leukemia: new insights.
Harrison CJ
Hematology Am Soc Hematol Educ Program; 2013; 2013():118-25. PubMed ID: 24319172
[TBL] [Abstract][Full Text] [Related]
36. Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia.
Richter A; Roolf C; Hamed M; Gladbach YS; Sender S; Konkolefski C; Knübel G; Sekora A; Fuellen G; Vollmar B; Murua Escobar H; Junghanss C
BMC Cancer; 2019 Mar; 19(1):202. PubMed ID: 30841886
[TBL] [Abstract][Full Text] [Related]
37. MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations.
Kerstjens M; Driessen EM; Willekes M; Pinhanços SS; Schneider P; Pieters R; Stam RW
Oncotarget; 2017 Feb; 8(9):14835-14846. PubMed ID: 27588400
[TBL] [Abstract][Full Text] [Related]
38. MiR-124 contributes to glucocorticoid resistance in acute lymphoblastic leukemia by promoting proliferation, inhibiting apoptosis and targeting the glucocorticoid receptor.
Liang YN; Tang YL; Ke ZY; Chen YQ; Luo XQ; Zhang H; Huang LB
J Steroid Biochem Mol Biol; 2017 Sep; 172():62-68. PubMed ID: 28578002
[TBL] [Abstract][Full Text] [Related]
39. Characterisation of the genomic landscape of CRLF2-rearranged acute lymphoblastic leukemia.
Russell LJ; Jones L; Enshaei A; Tonin S; Ryan SL; Eswaran J; Nakjang S; Papaemmanuil E; Tubio JM; Fielding AK; Vora A; Campbell PJ; Moorman AV; Harrison CJ
Genes Chromosomes Cancer; 2017 May; 56(5):363-372. PubMed ID: 28033648
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of ruxolitinib in acute lymphoblastic leukemia: A systematic review.
Kołodrubiec J; Kozłowska M; Irga-Jaworska N; Sędek Ł; Pastorczak A; Trelińska J; Młynarski W
Leuk Res; 2022 Oct; 121():106925. PubMed ID: 35939887
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]